Karyopharm Therapeutics Inc.
KPTI evidence brief
What we can confirm
- BioSniper Score:
- 3.7 / 10
- Market Cap:
- $36.5M
- Lead Asset:
- eltanexor (Phase 3)
What it means
What to watch
Prepared research question
What matters most for KPTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KPTI
Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage pharmaceutical company focused on developing and commercializing novel cancer therapies, primarily the XPO1 inhibitor selinexor (XPOVIO), with approved indications in multiple myeloma and ongoing late-stage trials in myelofibrosis and endometrial cancer.
Key risk: Cash runway risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 15 clinical trials · 1 catalyst · 1 FDA decision for Karyopharm Therapeutics Inc..
Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage pharmaceutical company focused on developing and commercializing novel cancer therapies, primarily the XPO1 inhibitor selinexor (XPOVIO), with approved indications in multiple myeloma and ongoing late-stage trials in myelofibrosis and endometrial cancer.
- Cash & equivalents of $55.0M as of 2026-06-30 [sec]
- Total revenue of $33.4M and net income of -$67.0M as of 2026-06-30 [sec]
- Shareholders' equity of -$330.2M as of 2026-06-30 [sec]
- XPOVIO net product revenue of $115M in fiscal year 2025 [sec · filed 2026-04-13]
- Phase 3 SENTRY trial in myelofibrosis top-line data expected March 2026 [sec · filed 2026-01-09]
What works
- XPOVIO has generated $115M in net product revenue in a competitive multiple myeloma market [sec · filed 2026-04-13]
- Selinexor has received regulatory approvals in more than 50 countries [sec · filed 2026-04-13]
- Operating costs reduced by 11% compared to 2024 [sec · filed 2026-04-13]
- Late-stage Phase 3 myelofibrosis trial enrollment completed [sec · filed 2026-04-13]
What to weigh
- Cash runway expected only into September 2026, with a $15.8M principal payment due September 10, 2026 [sec_mda · as of 2026-08-13]
- Substantial doubt about ability to continue as a going concern [sec · filed 2026-04-13]
- Shareholders' equity deeply negative at -$330.2M as of 2026-06-30 [sec]
- Failed endometrial cancer program noted [news · published 2026-08-13]
From the filings
Quoted directly from source documents.
Cash runway limited to September 2026
“We expect that our existing liquidity, including cash, cash equivalents, and investments as well as cash flow from net product revenue and license and other revenue, will enable us to fund our current operating plans into September 2026.”
SEC MD&A · August 13, 2026
Substantial doubt about going concern
“substantial doubt about our ability to continue as a going concern”
SEC filings · April 13, 2026
XPOVIO revenue in 2025
“generating $115 million in XPOVIO net product revenue in an increasingly competitive multiple myeloma market”
SEC filings · April 13, 2026
SENTRY trial data expected March 2026
“Phase 3 SENTRY trial evaluating selinexor in combination with once or twice-daily ruxolitinib versus placebo plus ruxolitinib in JAKi-naive myelofibrosis patients in March 2026”
SEC filings · January 9, 2026
Catalyst timeline
- 2035-08-14 · Patent_Expiry · SELINEXOR — Patent_Expiry: NDA212306 — Patent expiry for selinexor (NDA212306) occurs on this date, potentially opening the door for generic competition.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Liquidity expected to fund operations only into September 2026; $15.8M payment due Sep 10, 2026 [sec_mda · as of 2026-08-13]
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern [sec · filed 2026-04-13]
- Negative shareholders' equity — Shareholders' equity of -$330.2M as of 2026-06-30 [sec]
- Endometrial cancer program failure — Failed endometrial cancer program noted [news · published 2026-08-13]
What to watch
- Top-line data from Phase 3 SENTRY trial in myelofibrosis expected March 2026 [sec · filed 2026-01-09]
- Phase 3 XPORT-EC-042 trial in endometrial cancer data expected mid-2026 [sec · filed 2026-01-09]
- Ability to extend cash runway beyond September 2026 via financing or strategic alternatives [sec_mda · as of 2026-08-13]
- Outcome of $15.8M principal payment due September 10, 2026 [sec_mda · as of 2026-08-13]
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Karyopharm Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Karyopharm Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$67M
Lead: Approved
2 candidates
1 upcoming, next in ~3226d
0 buys · 8 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 25.5%
- Days to cover
- 3.4
- Shares short
- 5,718,250
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KPTI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Karyopharm Therapeutics Inc.?
Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage pharmaceutical company focused on developing and commercializing novel cancer therapies, primarily the XPO1 inhibitor selinexor (XPOVIO), with approved indications in multiple myeloma and ongoing late-stage trials in myelofibrosis and endometrial cancer.
What is Karyopharm Therapeutics Inc.'s lead drug candidate?
Karyopharm Therapeutics Inc.'s most advanced tracked candidate is eltanexor (Phase 3) for Myeloproliferative neoplasms and TP53 wild-type tumors.
What is Karyopharm Therapeutics Inc.'s next catalyst?
Karyopharm Therapeutics Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA212306" — expected August 14, 2035.
Who is the CEO of Karyopharm Therapeutics Inc.?
Mr. Richard A. Paulson M.B.A. is the chief executive officer of Karyopharm Therapeutics Inc. (KPTI).
Where is Karyopharm Therapeutics Inc. headquartered?
Karyopharm Therapeutics Inc. (KPTI) is headquartered in Newton, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.